Gina Hong1, Kevin Alby2, Sharon C W Ng3, Victoria Fleck3, Christina Kubrak4, Ronald C Rubenstein4, Daniel J Dorgan3, Steven M Kawut5, Denis Hadjiliadis3. 1. Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: gina.hong@pennmedicine.upenn.edu. 2. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. 3. Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. 4. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5. Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: The clinical effects of Aspergillus fumigatus in the cystic fibrosis (CF) airway, with the exception of allergic bronchopulmonary aspergillosis, is unclear. METHODS: CF adolescents and adults (age 14 years and older) underwent bacterial and semi-selective fungal culture testing to determine the prevalence of fungi in the CF respiratory tract and the independent association between the presence of Aspergillus fumigatus and clinical characteristics. RESULTS: Aspergillus fumigatus (10.3%) and Candida species (57.8%) were the most common filamentous fungi and yeast seen respectively in the sputa of 206 individuals with CF. Inhaled corticosteroid (ICS) use was more common in Aspergillus fumigatus-positive than Aspergillus fumigatusnegative (100% versus 75.8%, p = .01). Aspergillus fumigatus was significantly associated with lower respiratory domain score (β -8.74, 95% CI -16.6, -0.88, p = .03), representing worse respiratory-related quality of life, accounting for demographics, disease characteristics, and the presence of a pulmonary exacerbation. CONCLUSION: The presence of Aspergillus fumigatus in CF sputum was associated with worse respiratory quality of life in CF in a crosssectional, single center study. Longitudinal analysis examining the clinical implications of Aspergillus fumigatus on respiratory health over time is needed.
BACKGROUND: The clinical effects of Aspergillus fumigatus in the cystic fibrosis (CF) airway, with the exception of allergic bronchopulmonary aspergillosis, is unclear. METHODS: CF adolescents and adults (age 14 years and older) underwent bacterial and semi-selective fungal culture testing to determine the prevalence of fungi in the CF respiratory tract and the independent association between the presence of Aspergillus fumigatus and clinical characteristics. RESULTS:Aspergillus fumigatus (10.3%) and Candida species (57.8%) were the most common filamentous fungi and yeast seen respectively in the sputa of 206 individuals with CF. Inhaled corticosteroid (ICS) use was more common in Aspergillus fumigatus-positive than Aspergillus fumigatusnegative (100% versus 75.8%, p = .01). Aspergillus fumigatus was significantly associated with lower respiratory domain score (β -8.74, 95% CI -16.6, -0.88, p = .03), representing worse respiratory-related quality of life, accounting for demographics, disease characteristics, and the presence of a pulmonary exacerbation. CONCLUSION: The presence of Aspergillus fumigatus in CF sputum was associated with worse respiratory quality of life in CF in a crosssectional, single center study. Longitudinal analysis examining the clinical implications of Aspergillus fumigatus on respiratory health over time is needed.
Authors: Michelle A McMahon; Sanjay Haresh Chotirmall; Brian McCullagh; Peter Branagan; N G McElvaney; P M Logan Journal: Eur J Radiol Date: 2011-02-23 Impact factor: 3.528
Authors: Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri Journal: Am J Respir Crit Care Med Date: 2006-09-07 Impact factor: 21.405
Authors: Gregory S Sawicki; Lawrence Rasouliyan; Ann H McMullen; Jeffrey S Wagener; Susanna A McColley; David J Pasta; Alexandra L Quittner Journal: Pediatr Pulmonol Date: 2010-09-16
Authors: Philip M Farrell; Terry B White; Clement L Ren; Sarah E Hempstead; Frank Accurso; Nico Derichs; Michelle Howenstine; Susanna A McColley; Michael Rock; Margaret Rosenfeld; Isabelle Sermet-Gaudelus; Kevin W Southern; Bruce C Marshall; Patrick R Sosnay Journal: J Pediatr Date: 2017-02 Impact factor: 4.406
Authors: Alexandra L Quittner; Gregory S Sawicki; Ann McMullen; Lawrence Rasouliyan; David J Pasta; Ashley Yegin; Michael W Konstan Journal: Qual Life Res Date: 2011-10-14 Impact factor: 4.147
Authors: Catherine A Coughlan; Sanjay H Chotirmall; Julie Renwick; Tidi Hassan; Teck Boon Low; Gudmundur Bergsson; Ahmed Eshwika; Kathleen Bennett; Katie Dunne; Catherine M Greene; Cedric Gunaratnam; Kevin Kavanagh; Patrick M Logan; Philip Murphy; Emer P Reeves; Noel G McElvaney Journal: Am J Respir Crit Care Med Date: 2012-08-16 Impact factor: 21.405
Authors: Axel Blomquist; Malin Inghammar; Mahasin Al Shakirchi; Petrea Ericson; Christina Krantz; Marcus Svedberg; Anders Lindblad; Lisa I Påhlman Journal: BMC Pulm Med Date: 2022-07-05 Impact factor: 3.320
Authors: Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Bumhee Yang; Taehee Kim; Jiin Ryu; Hye Yun Park; Bin Hwangbo; Sun-Young Kong; Yong-Soo Kwon; Seung Jun Lee; Seung Won Ra; Yeon-Mok Oh; Jang Won Sohn; Kang Hyeon Choe; Hayoung Choi; Hyun Lee Journal: J Pers Med Date: 2021-05-17
Authors: Alexander J Currie; Ellen T Main; Heather M Wilson; Darius Armstrong-James; Adilia Warris Journal: Front Cell Infect Microbiol Date: 2020-07-24 Impact factor: 5.293